A novel mouse model for evaluation and prediction of HLA-A2-restricted CEA cancer vaccine responses.

摘要: Summary: Human leukocyte antigen (HLA)-A2.1 transgenic mice (HHD) represent a valuable model to study and predict the immunogenicity of vaccines against pathogens. However, HHD are unsuitable for in vivo studies cancer human tumor-associated antigens because they lack T-cell tolerance that is key define potency treatment. In this study, we developed HHD/carcinoembryonic P(CEA) hybrid by breeding homozygous CEA with HHD. These express CEA, present epitopes solely through HLA-A2.1 molecules constitute unique animal HLA-A2.1-restricted immune response CEA-based vaccine. Owing tolerance, HHD/CEA show limited expansion different restricted receptor repertoire after antigen-specific stimulation. Our data genetic vectors expressing peptide-based able efficiently break elicit strong epitopes. Most importantly, efficient lysis + /HLA-A2.1 tumor cells was observed significant protection achieved HHD/CEA-vaccinated mice. Hence, provides relevant evaluation potential efficacy vaccines.